Collegium Pharmaceutical (COLL) Total Current Liabilities (2014 - 2026)

Collegium Pharmaceutical's Total Current Liabilities history runs 13 years deep, the most recent figure standing at $435.0 million for Q1 2026.

• In Q1 2026, Total Current Liabilities fell 10.63% year-over-year to $435.0 million; the TTM figure through Mar 2026 stood at $435.0 million (down 10.63% YoY), while the FY2025 annual figure was $440.0 million, down 13.64% from the prior year.
• Total Current Liabilities was $435.0 million for Q1 2026 at Collegium Pharmaceutical, down from $440.0 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $509.5 million in Q4 2024 to a low of $373.6 million in Q1 2022.
• Historically, Total Current Liabilities has averaged $444.9 million across 5 years, with a median of $446.4 million in 2024.
• The sharpest annual moves came in 2022 and 2025: Total Current Liabilities surged 82.99% in 2022, then fell 13.64% in 2025.
• A 5-year view of Total Current Liabilities shows it stood at $433.7 million in 2022, then gained by 5.58% to $457.9 million in 2023, then climbed by 11.27% to $509.5 million in 2024, then dropped by 13.64% to $440.0 million in 2025, then fell by 1.15% to $435.0 million in 2026.
• The last three Total Current Liabilities figures came in at $435.0 million (Q1 2026), $440.0 million (Q4 2025), and $452.9 million (Q3 2025), per Business Quant data.